一个行业的角度,对氨酸酶联合配制的生物制药
Jeremy Guo1, Jingwen Weng1, Fangyuan Zhou1
1Drug Product Development, WuXi Biologics, Ireland.
概括
生物制药的皮下注射 (SC) 是通过氨基酶增强,使得较大的体积和降低成本相比静脉注射 (IV) 交付. 重组人类PH20是开发这些先进的SC配方的关键酶.
科学领域:
- 生物制药开发 生物制药开发
- 药物输送系统 药物输送系统
- 酶学 是一种酶学.
背景情况:
- 生物制药的皮下 (SC) 输送在时间和成本方面比静脉输送 (IV) 提供了优势.
- 从历史上看,SC注射仅限于2mL或更少的体积.
- hialuronidase 已成为克服 SC 生物制药输送量限制的关键技术.
研究的目的:
- 系统地审查商业上可用的氨酸酶联合配方生物制药.
- 突出未来氨酸酶联合配方产品的关键发展方面.
- 为开发先进的SC生物制药配方提供全面的参考.
主要方法:
- 对已批准的氨酸酶联合配方生物制品进行系统审查.
- 开发考虑因素的分析,包括酶选择,配方,过程开发和监管途径.
- 探索与大容量自动注射器设备的集成.
主要成果:
- 从2024年开始,监管机构已经批准了8种氨基酶联合配方的生物制药产品.
- 由于其疗效和安全性,重组人类PH20被确定为联合配方的主要候选者.
- 早期的监管参与对于导航每个治疗剂的独特开发路径至关重要.
结论:
- 氨酸酶联合配方显著扩大了生物制药的SC药物输送潜力.
- 战略开发,包括酶选择和监管互动,对于成功的产品推出至关重要.
- 本综述作为一个实用指南,以推进氨酸酶联合配制的生物制药,使全球患者受益.
相关概念视频
Bioequivalence: Overview
907
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
907
Biopharmaceutics and Pharmacokinetics: Overview
1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K
Factors Influencing Drug Absorption: Pharmaceutical Parameters
113
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
113
Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
Prodrugs
2.4K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.4K
Factors Influencing Bioavailability: First-Pass Elimination
6.0K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.0K


